GLP-1 Evidence

Not medical advice. A record of published research and our assessments of it. The limits

GLP-1 drugs and healthy aging

Semaglutide, tirzepatide and related drugs are increasingly discussed as treatments for aging itself. This collection records what the published evidence actually shows, and how much of it applies to healthy normal-weight adults aged 55–75.

Studies recorded
6350 enrolled the target group directly.
Claims assessed
22Each claim is a single testable statement, with the evidence for and against it.
Open questions
11What is not known, and what study would settle it.
Trials watched
324Registered trials, checked for status and date changes.
Snapshot
Nov 11, 2026

Counts are from the snapshot date above. Where a study is marked “facts auto-extracted”, its details were taken from the abstract by machine and are not published as fact, whether or not a person has reviewed the record.

01The question

The question every entry answers

Does this study show benefit or harm in people without obesity or diabetes? Most GLP-1 research enrolled people with one or both. An effect in those groups is recorded as evidence about those groups, and is never counted as evidence for healthy normal-weight adults aged 55–75.

Much of the benefit seen in trials may also come from weight loss itself rather than from the drug. Every study records whether that possibility was tested.

02Claims

Claims, and where the evidence stands

All 22 claims

03What changed

Recent changes in the evidence

04Trials to watch

Trials enrolling people without obesity

All watched trials